Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals develops and licenses medicines used to treat serious diseases including cancer, infectious diseases, diabetes, osteoporosis, and kidney disease. The company owns or has rights to drugs like KYPROLIS for multiple myeloma, VEKLURY for COVID-19, FILSPARI for kidney disease, and TZIELD to delay type 1 diabetes in children and young adults. Some of their medicines are approved and available to patients, while others are still being tested in clinical trials. The company was founded in 1987 and is based in Florida.